Calls for papers
-
Opiant Pharmaceuticals said that it has initiated a Phase 2 trial of its OPNT002 intranasal naltrexone for the treatment of alcohol use disorder that is expected to enroll approximately 300 patients, with results expected in… Read more . . .
-
Glenmark Pharmaceuticals announced that Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, has acquired the rights to commercialize Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray in Singapore, Hong Kong and Vietnam. Lotus will make… Read more . . .
-
According to Pneumagen, the company has closed a £3.8 million funding round led by Thairm Bio and Scottish Enterprise, with proceeds intended to fund GMP manufacturing and Phase 2 development of its Neumifil carbohydrate binding… Read more . . .
-
The Cystic Fibrosis Foundation has awarded funding to Feldan Therapeutics for development of the company’s Feldan Shuttle technology for pulmonary delivery of drugs to treat cystic fibrosis. Neither the company nor the CFF disclosed the… Read more . . .
-
Australian biotech Medlab Clinical said that it has received a grant from the New South Wales government for development of a proof-of-concept intranasal vaccine based on its NanoCelle “sub-micron delivery platform” technology. The company added… Read more . . .
-
Open Orphan spin-out Poolbeg Pharma said that it has acquired an exclusive license for an intranasal RNA-based immunotherapy for the prevention and treatment of viral respiratory infections from the University of Warwick. According to the company, in… Read more . . .
-
Levo Therapeutics announced that the FDA has issued a complete response letter to the company’s NDA for LV-101 intranasal carbetocin for the treatment of excessive hunger and anxiety associated with Prader-Willi syndrome (PWS). The FDA… Read more . . .
-
The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) has announced that Kindeva Drug Delivery Global Respiratory Product Development Manager Mike Needham will serve as Vice Chair of the IPAC-RS board until June 1,… Read more . . .
-
Glenmark Pharmaceuticals announced that it has received FDA approval of its NDA for Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in patients aged 12 and older. The… Read more . . .
-
ReCode Therapeutics, which recently raised $80 million for development of inhaled genetic therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), has announced the appointment of former Theravance Biopharma executive Shehnaaz Suliman as CEO and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA